NovoCure (NVCR) Insider Trading & Ownership $14.35 +0.19 (+1.34%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$14.32 -0.03 (-0.17%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NovoCure (NASDAQ:NVCR) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.52%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$1.23MNumber OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$24.86K Get NVCR Insider Trade Alerts Want to know when executives and insiders are buying or selling NovoCure stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVCR Insider Buying and Selling by Quarter NovoCure Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/5/2025Ashley CordovaCEOBuy81,550$12.22$996,541.00 7/29/2025Christoph BrackmannCFOBuy20,000$11.59$231,800.00 11/1/2024Frank X LeonardEVPSell598$15.94$9,532.12 11/1/2024Mukund ParavasthuCOOSell160$15.88$2,540.80 10/31/2024Michal Nath PuriInsiderSell810$15.79$12,789.90 (Data available from 1/1/2013 forward) NVCR Insider Trading Activity - Frequently Asked Questions Who is on NovoCure's Insider Roster? The list of insiders at NovoCure includes Asaf Danziger, Ashley Cordova, Christoph Brackmann, Frank X Leonard, Michal Nath Puri, Mukund Paravasthu, Pritesh Shah, Uri Weinberg, W Anthony Vernon, and Wilhelmus Cm Groenhuysen. Learn more on insiders at NVCR. What percentage of NovoCure stock is owned by insiders? 5.52% of NovoCure stock is owned by insiders. Learn more on NVCR's insider holdings. Which NovoCure insiders have been buying company stock? The following insiders have purchased NVCR shares in the last 24 months: Ashley Cordova ($996,541.00), and Christoph Brackmann ($231,800.00). How much insider buying is happening at NovoCure? Insiders have purchased a total of 101,550 NVCR shares in the last 24 months for a total of $1,228,341.00 bought. Which NovoCure insiders have been selling company stock? The following insiders have sold NVCR shares in the last 24 months: Ashley Cordova ($13,856.32), Frank X Leonard ($83,433.81), Michal Nath Puri ($12,789.90), Mukund Paravasthu ($2,540.80), Pritesh Shah ($4,832.30), W Anthony Vernon ($23,029.96), and Wilhelmus Cm Groenhuysen ($53,259.38). How much insider selling is happening at NovoCure? Insiders have sold a total of 11,523 NovoCure shares in the last 24 months for a total of $193,742.47 sold. NovoCure Key ExecutivesMr. William F. Doyle (Age 62)Executive Chairman Compensation: $1.43MMr. Asaf Danziger (Age 58)CEO & Director Compensation: $1.52MMs. Ashley Cordova (Age 45)Chief Financial Officer Compensation: $814.81k1 recent tradesMr. Wilhelmus C. M. Groenhuysen (Age 66)Chief Operating Officer Compensation: $965.56kMr. Barak Ben Arye (Age 47)General Counsel Compensation: $761.97kMr. Frank LeonardExecutive VP & President of Novocure OncologyProf. Yoram Palti M.D. (Age 86)Ph.D., Founder & CTO Compensation: $282.51kDr. Moshe Giladi Ph.D. (Age 54)Chief Science Officer Ms. Ingrid GoldbergVP of Investor RelationsMr. Michael Puri (Age 55)Chief Human Resources Officer More Insider Trading Tools from MarketBeat Related Companies IRTC Insider Transactions BLCO Insider Transactions GKOS Insider Transactions TMDX Insider Transactions NVST Insider Transactions SLNO Insider Transactions LIVN Insider Transactions WRBY Insider Transactions INSP Insider Transactions EYE Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Marvell Insiders Buy Shares—Should Investors Follow Suit?This Insider Just Made a Massive Bet on Transocean's ComebackInsider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t WorryTop Insider Buys and Sells From September: Buy, Sell, or Hold? This page (NASDAQ:NVCR) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
